• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arcturus Therapeutics Holdings Inc (NQ: ARCT )

    26.98 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 26.98
    Bid (Size) 24.11 (1)
    Ask (Size) 30.69 (3)
    Prev. Close 26.98
    Today's Range 26.98 - 26.98
    52wk Range 17.52 - 43.81
    Shares Outstanding 26,562,951
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
    Via Benzinga
    ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023
    ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
    Via InvestorPlace

    Performance

    YTD
    -18.46%
    -18.46%
    1 Month
    -22.45%
    -22.45%
    3 Month
    -16.21%
    -16.21%
    6 Month
    +42.53%
    +42.53%
    1 Year
    -3.92%
    -3.92%

    More News

    Read More
    Recap: Arcturus Therapeutics Q4 Earnings
    Via Benzinga
    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Evaluating NASDAQ:ARCT for Growth Investment Opportunities.
    Via Chartmill
    Is NASDAQ:ARCT suited for growth investing?
    Via Chartmill
    Earnings Scheduled For March 7, 2024
    Via Benzinga
    Earnings Preview: Arcturus Therapeutics
    Via Benzinga
    7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
    Via InvestorPlace
    Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
    Via InvestorPlace
    3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
    Via InvestorPlace
    Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
    From Arcturus Therapeutics
    Via Business Wire
    Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).
    Via Chartmill
    ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations
    Via Chartmill
    CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
    From Arcturus Therapeutics
    Via Business Wire
    7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
    Via InvestorPlace
    3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
    Via InvestorPlace
    Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
    Via Benzinga
    5 Value Stocks In The Healthcare Sector
    Via Benzinga
    Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Why the growth investor may take a look at NASDAQ:ARCT.
    Via Chartmill
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.